

Integrated Filing (Finance) Ind AS

BAFNA PHARMACEUTICALS LIMITED

General Information

Scrip code*	532989	
NSE Symbol*	BAFNAPH	
MSEI Symbol*	NOTLISTED	
ISIN*	INE878I01022	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	12-08-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	07-08-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	First quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended		
Segment Reporting	Single segment	
Description of single segment	Pharmaceuticals	
Start date of board meeting	12-08-2025	
Start time of board meeting	14:30:00	
End date of board meeting	12-08-2025	
End time of board meeting	15:45:00	
Whether cash flow statement is applicable on company		
Type of cash flow statement		
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	false	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	false	Textual Information(1)

Text Block

Textual Information(1)	The Company has not defaulted on repayment of Loans and Debt Securities.
---------------------------	--

Financial Results - Ind-AS

Amount in (Lakhs)

	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025	01-04-2025
Date of end of reporting period	30-06-2025	30-06-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.	
1 Income		
Revenue from operations	3,462.40	3,462.40
Other income	59.56	59.56
Total income	3,521.96	3,521.96
2 Expenses		
(a) Cost of materials consumed	1,755.78	1,755.78
(b) Purchases of stock-in-trade	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(21.96)	(21.96)
(d) Employee benefit expense	563.99	563.99
(e) Finance costs	90.54	90.54
(f) Depreciation, depletion and amortisation expense	136.99	136.99
(g) Other Expenses		
1 Manufacturing Expenses	507.96	507.96
2 Other Expenses	149.77	149.77
Total other expenses	657.73	657.73
Total expenses	3,183.07	3,183.07
Total profit before exceptional items and tax	338.89	338.89
4 Exceptional items	0.00	0.00
Total profit before tax	338.89	338.89
6 Tax expense		
7 Current tax	0.00	0.00
8 Deferred tax	0.00	0.00
Total tax expenses	0.00	0.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
Net Profit Loss for the period from continuing operations	338.89	338.89
12 Profit (loss) from discontinued operations before tax	0.00	0.00
13 Tax expense of discontinued operations	0.00	0.00
Net profit (loss) from discontinued operation after tax	0.00	0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
Total profit (loss) for period	338.89	338.89
17 Other comprehensive income net of taxes	(4.62)	(4.62)
Total Comprehensive Income for the period	334.27	334.27
19 Total profit or loss, attributable to		
Profit or loss, attributable to owners of parent		
Total profit or loss, attributable to non-controlling interests		
Total Comprehensive income for the period attributable to		
Comprehensive income for the period attributable to owners of parent		
Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21 Details of equity share capital		
Paid-up equity share capital	2,365.63	2,365.63
Face value of equity share capital	10.00	10.00
22 Reserves excluding revaluation reserve		

23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	1.43	1.43
	Diluted earnings (loss) per share from continuing operations	1.43	1.43
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	1.43	1.43
	Diluted earnings (loss) per share from continuing and discontinued operations	1.43	1.43
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	<p>Notes:</p> <ol style="list-style-type: none">1. The above unaudited financial results for the quarter ended 30th June 2025 have been reviewed by the Audit Committee at their meeting held on 12th August 2025 and thereafter approved by the Board of Directors of the Company at their meeting held on 12th August 2025. The Statutory Auditors have conducted a "Limited Review" of these financial results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.2. The figures for the quarter ended 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year ended 31st March 2025 and the unaudited published year to date figures upto 31st December 2024.3. The figures for the corresponding previous periods have been regrouped and reclassified wherever necessary, to make them comparable.4. The above unaudited financial results have been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.5. Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Indian Accounting Standards 108 ("Ind AS 108") as notified under Section 133 of the Companies Act, 2013 is considered as the only segment.6. The Company is required to maintain the Minimum Public Shareholding ("MPS") as prescribed under Rule 19A of the Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Promoter of the Company had issued Notice of Offer for Sale in the earlier period for certain equity shares. However, the said offer had not garnered the requisite number of subscribers to reach the MPS Criteria. The Promoters took steps to regularise the statutory non-compliance and initiated further measures to achieve the required public shareholding. As a result, the Promoters completed the sale of shares through the OFS, and the Company achieved the prescribed Minimum Public Shareholding as on 2nd April 2025 and in the process of obtaining waiver for the penalty levied by the Stock Exchanges.7. "Exceptional items for the year ended 31st March 2025 represents the following: (a) Derecognition of certain inventory items amounting to INR 37.56 Lakhs (b) Derecognition of Intangible Asset under Development amounting to INR 177 Lakhs. The management has derecognised the Intangible Asset under Development as it does not foresee that any future economic benefit would accrue to the Company in respect of the expenditure incurred in the earlier financial years towards obtaining certain product registrations."8. The Board of Directors of the Company, at its meeting held on 13th August, 2024, had approved the sale of assets of the Manufacturing unit of the Company located at Madhavaram, subject to regulatory approvals, which was also approved by the shareholders at the AGM held on 25th September, 2024. Accordingly, the assets of the Madhavaram unit was classified as "Assets Held for Sale" and the management has concluded the sale process in the current quarter.
------------------------	--

Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025	01-04-2025
Date of end of reporting period	30-06-2025	30-06-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]		
1 Amount of items that will not be reclassified to profit and loss		
Total Amount of items that will not be reclassified to profit and loss		
2 Income tax relating to items that will not be reclassified to profit or loss	4.62	4.62
3 Amount of items that will be reclassified to profit and loss		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	(4.62)	(4.62)

Details of Impact of Audit Qualification

Whether results are audited or unaudited		Unaudited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33(3)(d) of SEBI(LODR) Regulation, 2015: The company declares that its Statutory Auditor / s have issued an Audit Report with unmodified opinion for the period on Standalone results		true	
Sr.No	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Brahmayya & Co	true	30-04-2027